Meridian Bioscience (VIVO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Meridian Bioscience is a diversified life science company with a dual-pronged strategy in Diagnostics and Life Science reagents. The company leverages deep expertise in immunology and molecular biology to manufacture best-in-class diagnostic tests and the essential components used by other diagnostic manufacturers. Recent achievements, such as winning the CDC's Lead Detect Prize, underscore its leadership in public health testing and its strategic focus on expanding its ambient-stable NGS portfolio to drive future growth.

Infectious DiseaseGastrointestinalPublic HealthAutoimmune

Technology Platform

Proprietary platforms in immunology and molecular biology for developing and manufacturing diagnostic tests (e.g., Revogene system) and critical life science reagents (antibodies, antigens, ambient-stable NGS kits).

Opportunities

Significant opportunities exist in the growing demand for decentralized diagnostic testing and ambient-stable reagents, particularly in NGS.

Meridian's recent CDC Lead Detect Prize win also opens a new public health market for innovative lead testing solutions.

Risk Factors

Key risks include intense competition from larger diagnostic conglomerates, regulatory and reimbursement hurdles for new tests, and execution risk in commercializing new platform innovations like its ambient-stable NGS portfolio.

Competitive Landscape

Meridian competes with large IVD players (e.g., Abbott, Roche) in diagnostics and major reagent suppliers (e.g., Thermo Fisher) in life science. Its strategy relies on niche leadership, vertical integration, and technological differentiation in areas like ambient-stable formulations.

More companies in Diagnostics & Precision Medicine →More companies in United States →